Tag Archives: Glaxo

GlaxoSmithKline v. Banner Pharmacaps – Written Description Requirement 101

In a short opinion dated February 24, 2014 (App. Nos. 2013-1593, -94, -95, -98), a Fed. Cir. panel made short work of the defendants’ attempt to invalidate a Glaxo claim in U.S. Pat. No. 5,565,467, to dutasteride “or a pharmaceutically … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , | Leave a comment

Director Kappos Kills Prosecution Regulations Package

Two years of fear and loathing have ended, as the USPTO has announced that it is rescinding the “Continuations” and “Claims” rules that have been hanging over the heads of practitioners, and will move to dismiss/vacate the pending lawsuit over … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , , , , | 1 Comment